Gregory M. Cote, Ph.D.
Affiliations: | 2004 | Boston University, Boston, MA, United States |
Area:
Molecular BiologyGoogle:
"Gregory Cote"Parents
Sign in to add mentor| Douglas B. Sawyer | grad student | 2004 | Boston University | |
| (Neuregulin-1 expression and function in the heart.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tap WD, Villalobos VM, Cote GM, et al. (2020) Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902492 |
| Cote GM, DeLaney TF, Miao R, et al. (2020) Updated 5-year local control (LC), metastasis-free survival (MFS), and overall survival (OS) data from a phase I study of nilotinib plus radiation (RT) in high-risk chordoma. Journal of Clinical Oncology. 38: e23505-e23505 |
| Mellinghoff IK, Peters KB, Cloughesy TF, et al. (2020) Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population. Journal of Clinical Oncology. 38: 2504-2504 |
| Gounder MM, Stacchiotti S, Schoffski P, et al. (2020) Efficacy, safety, and immune priming effect of tazemetostat in patients with epithelioid sarcoma. Journal of Clinical Oncology. 38: 11564-11564 |
| Nathenson M, Choy E, Carr ND, et al. (2020) Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort. Journal of Clinical Oncology. 38: 11559-11559 |
| Cote GM, Choy E, Chen T, et al. (2019) A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. European Journal of Cancer (Oxford, England : 1990). 126: 21-32 |
| Widemann BC, Lu Y, Reinke D, et al. (2019) Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019: 7656747 |
| Luke JJ, Sharma M, Sanborn RE, et al. (2019) A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms. Journal of Clinical Oncology. 37: TPS2661-TPS2661 |
| Cote GM, Chawla SP, Burgess MA, et al. (2019) CBT-1 in combination with doxorubicin in patients with metastatic, unresectable sarcomas who previously progressed on doxorubicin. Journal of Clinical Oncology. 37: TPS11077-TPS11077 |
| Stacchiotti S, Schoffski P, Jones R, et al. (2019) Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950). Journal of Clinical Oncology. 37: 11003-11003 |